 <h1>Nucala Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>mepolizumab</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about mepolizumab. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Nucala.</p><h2>In Summary</h2><p><b>More frequent side effects include:</b> injection site reaction.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to mepolizumab: subcutaneous powder for solution, subcutaneous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, mepolizumab (the active ingredient contained in Nucala) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking mepolizumab:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Blurred vision</li>
<li>confusion</li>
<li>cough</li>
<li>difficulty with breathing</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>fast heartbeat</li>
<li>hives or welts, itching, or skin rash</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>noisy breathing</li>
<li>painful blisters on the trunk of the body</li>
<li>redness of the skin</li>
<li>sweating</li>
<li>tightness in the chest</li>
<li>unusual tiredness or weakness</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of mepolizumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
<li>headache</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Back pain</li>
<li>bladder pain</li>
<li>bloody or cloudy urine</li>
<li>chills</li>
<li>diarrhea</li>
<li>difficult, burning, or painful urination</li>
<li>fever</li>
<li>frequent urge to urinate</li>
<li>general feeling of discomfort or illness</li>
<li>joint pain</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>muscle aches, pains, or spasms</li>
<li>nausea</li>
<li>runny nose</li>
<li>shivering</li>
<li>skin rash, encrusted, scaly, and oozing</li>
<li>sore throat</li>
<li>sweating</li>
<li>trouble sleeping</li>
<li>upper abdominal or stomach pain</li>
<li>vomiting</li>
</ul><p>
<!-- end subcutaneous powder for solution, subcutaneous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to mepolizumab: subcutaneous powder for injection, subcutaneous solution</i></p><h3>General</h3><p>The more commonly reported side effects were headache, injection site reactions, and back pain.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 19%)</p>
<p><b>Frequency not reported</b>: Dizziness<sup>[Ref]</sup></p><p>Dizziness occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Systemic non-allergic/administration-related reactions (including rash, flushing, myalgia), systemic/hypersensitivity reactions (including rash, pruritus, headache, myalgia)</p>
<p><b>Frequency not reported</b>: Allergic rhinitis, angioedema, urticaria<sup>[Ref]</sup></p><p>Many systemic reactions occurred on the day of dosing.  Systemic reactions occurred in 10% of patients treated with this drug compared to 7% of placebo-treated patients.  Non-allergic reactions occurred in 2% of patients given this drug versus 3% of patients with placebo; allergic systemic reactions occurred in 1% and 2% of patients given this drug or placebo, respectively.</p>
<p></p>
<p>Allergic rhinitis occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.<sup>[Ref]</sup></p><h3>Local</h3><p>Injection site reactions occurred in 8% and 3% of patients given this drug or placebo, respectively.  The reactions more commonly occurred within the first 3 injections, with a decrease in frequency on subsequent injections.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Injection site reactions (e.g., pain, swelling, erythema, itching, burning)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Influenza, anti-mepolizumab (the active ingredient contained in Nucala) antibody formation</p>
<p><b>Frequency not reported</b>: Viral infection<sup>[Ref]</sup></p><p>In a clinical trial, 6% of patients developed anti-mepolizumab antibodies; these antibodies were shown to slightly increase drug clearance, but the clinical relevance is unknown.</p>
<p></p>
<p>Viral infection occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Pruritus, eczema</p>
<p><b>Frequency not reported</b>: Rash, flushing, herpes zoster reaction<sup>[Ref]</sup></p><p>Rash and herpes zoster occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Musculoskeletal pain occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Back pain, muscle spasms</p>
<p><b>Frequency not reported</b>: Musculoskeletal pain, myalgia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Upper abdominal pain</p>
<p><b>Frequency not reported</b>: Gastroenteritis, abdominal pain, nausea, toothache, vomiting<sup>[Ref]</sup></p><p>Gastroenteritis, abdominal pain, nausea, toothache, and vomiting occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.<sup>[Ref]</sup></p><h3>Other</h3><p>Asthenia, ear infection, and pyrexia occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Fatigue, pyrexia</p>
<p><b>Frequency not reported</b>: Asthenia, ear infection<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Lower respiratory tract infection, pharyngitis, nasal congestion</p>
<p><b>Frequency not reported</b>: Bronchitis, dyspnea, nasopharyngitis, viral respiratory tract infection, bronchospasm<sup>[Ref]</sup></p><p>Bronchitis, dyspnea, lower respiratory tract infection, nasal congestion, nasopharyngitis, pharyngitis, and viral respiratory tract infection occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Frequency not reported</b>: Hypotension<sup>[Ref]</sup></p><h3>Renal</h3><p>Cystitis occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Cystitis<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Nucala (mepolizumab)." GlaxoSmithKline, Research Triangle Park, NC. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>How long does it take for Nucala to work?</li>
<li>Can Nucala cause weight gain?</li>
<li>Can Nucala be self-administered?</li>
<li>What is Nucala (mepolizumab) used for and how is it given?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Nucala (mepolizumab)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>56 Reviews</li>
<li>Drug class: interleukin inhibitors</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Nucala &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Eosinophilic Granulomatosis with Polyangiitis</li>
<li>Hypereosinophilic Syndrome</li>
<li>Asthma</li>
<li>Asthma, Maintenance</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to mepolizumab: subcutaneous powder for injection, subcutaneous solution</i></p><h3>General</h3><p>The more commonly reported side effects were headache, injection site reactions, and back pain.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 19%)</p><p><b>Frequency not reported</b>: Dizziness<sup>[Ref]</sup></p><p>Dizziness occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Systemic non-allergic/administration-related reactions (including rash, flushing, myalgia), systemic/hypersensitivity reactions (including rash, pruritus, headache, myalgia)</p><p><b>Frequency not reported</b>: Allergic rhinitis, angioedema, urticaria<sup>[Ref]</sup></p><p>Many systemic reactions occurred on the day of dosing.  Systemic reactions occurred in 10% of patients treated with this drug compared to 7% of placebo-treated patients.  Non-allergic reactions occurred in 2% of patients given this drug versus 3% of patients with placebo; allergic systemic reactions occurred in 1% and 2% of patients given this drug or placebo, respectively.</p><p></p><p>Allergic rhinitis occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.<sup>[Ref]</sup></p><h3>Local</h3><p>Injection site reactions occurred in 8% and 3% of patients given this drug or placebo, respectively.  The reactions more commonly occurred within the first 3 injections, with a decrease in frequency on subsequent injections.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Injection site reactions (e.g., pain, swelling, erythema, itching, burning)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Influenza, anti-mepolizumab (the active ingredient contained in Nucala) antibody formation</p><p><b>Frequency not reported</b>: Viral infection<sup>[Ref]</sup></p><p>In a clinical trial, 6% of patients developed anti-mepolizumab antibodies; these antibodies were shown to slightly increase drug clearance, but the clinical relevance is unknown.</p><p></p><p>Viral infection occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Pruritus, eczema</p><p><b>Frequency not reported</b>: Rash, flushing, herpes zoster reaction<sup>[Ref]</sup></p><p>Rash and herpes zoster occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Musculoskeletal pain occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Back pain, muscle spasms</p><p><b>Frequency not reported</b>: Musculoskeletal pain, myalgia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Upper abdominal pain</p><p><b>Frequency not reported</b>: Gastroenteritis, abdominal pain, nausea, toothache, vomiting<sup>[Ref]</sup></p><p>Gastroenteritis, abdominal pain, nausea, toothache, and vomiting occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.<sup>[Ref]</sup></p><h3>Other</h3><p>Asthenia, ear infection, and pyrexia occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Fatigue, pyrexia</p><p><b>Frequency not reported</b>: Asthenia, ear infection<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Lower respiratory tract infection, pharyngitis, nasal congestion</p><p><b>Frequency not reported</b>: Bronchitis, dyspnea, nasopharyngitis, viral respiratory tract infection, bronchospasm<sup>[Ref]</sup></p><p>Bronchitis, dyspnea, lower respiratory tract infection, nasal congestion, nasopharyngitis, pharyngitis, and viral respiratory tract infection occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Frequency not reported</b>: Hypotension<sup>[Ref]</sup></p><h3>Renal</h3><p>Cystitis occurred in at least 3% of patients treated with this drug in a controlled, long-term clinical study.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Cystitis<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Nucala (mepolizumab)." GlaxoSmithKline, Research Triangle Park, NC. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>How long does it take for Nucala to work?</li>
<li>Can Nucala cause weight gain?</li>
<li>Can Nucala be self-administered?</li>
<li>What is Nucala (mepolizumab) used for and how is it given?</li>
</ul><h2>More about Nucala (mepolizumab)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>56 Reviews</li>
<li>Drug class: interleukin inhibitors</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Nucala &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Eosinophilic Granulomatosis with Polyangiitis</li>
<li>Hypereosinophilic Syndrome</li>
<li>Asthma</li>
<li>Asthma, Maintenance</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>